Christel Josefa Maria de Blok1, Maartje Klaver1, Chantal Maria Wiepjes1, Nienke Marije Nota1, Annemieke Corine Heijboer2,3, Alessandra Daphne Fisher4, Thomas Schreiner5, Guy T'Sjoen6, Martin den Heijer1. 1. Department of Endocrinology and Center of Expertise on Gender Dysphoria, VU University Medical Center, Amsterdam, The Netherlands. 2. Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Center, Amsterdam, The Netherlands. 3. Laboratory of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands. 4. Sexual Medicine and Andrology Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy. 5. Department of Endocrinology, Oslo University Hospital, Oslo, Norway. 6. Department of Endocrinology and Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.
Abstract
Context: Breast development is a key feature of feminization and therefore important to transwomen (male-to-female transgender persons). It is not exactly known when breast development starts after initiating cross-sex hormone therapy (CHT) and how much growth may be expected. Objective: To investigate breast development in transwomen during their first year of CHT and whether clinical or laboratory parameters predict breast development. Design: This study was performed as part of the European Network for the Investigation of Gender Incongruence, which is a prospective multicenter cohort study. Setting: Gender clinics in Amsterdam, Ghent, and Florence. Participants: Transwomen who completed the first year of CHT (n = 229). Intervention: CHT. Main Outcome Measures: Breast development in centimeter and cup size. Results: The median age of the included transwomen was 28 years (range, 18 to 69). Mean breast-chest difference increased to 7.9 ± 3.1 cm after 1 year of CHT, mainly resulting in less than an AAA cup size (48.7%). Main breast development occurred in the first 6 months of therapy. Serum estradiol levels did not predict breast development after 1 year of CHT (first quartile, 3.6 cm [95% confidence interval (CI), 2.7 to 4.5], second quartile, 3.2 cm [95% CI, 2.3 to 4.2], third quartile, 4.4 cm [95% CI, 3.5 to 5.3], and fourth quartile, 3.6 cm [95% CI, 2.7 to 4.5]). Conclusion: This study shows that, after 1 year of CHT, breast development is modest and occurs primarily in the first 6 months. No clinical or laboratory parameters were found that predict breast development.
Context: Breast development is a key feature of feminization and therefore important to transwomen (male-to-female transgender persons). It is not exactly known when breast development starts after initiating cross-sex hormone therapy (CHT) and how much growth may be expected. Objective: To investigate breast development in transwomen during their first year of CHT and whether clinical or laboratory parameters predict breast development. Design: This study was performed as part of the European Network for the Investigation of Gender Incongruence, which is a prospective multicenter cohort study. Setting: Gender clinics in Amsterdam, Ghent, and Florence. Participants: Transwomen who completed the first year of CHT (n = 229). Intervention: CHT. Main Outcome Measures: Breast development in centimeter and cup size. Results: The median age of the included transwomen was 28 years (range, 18 to 69). Mean breast-chest difference increased to 7.9 ± 3.1 cm after 1 year of CHT, mainly resulting in less than an AAA cup size (48.7%). Main breast development occurred in the first 6 months of therapy. Serum estradiol levels did not predict breast development after 1 year of CHT (first quartile, 3.6 cm [95% confidence interval (CI), 2.7 to 4.5], second quartile, 3.2 cm [95% CI, 2.3 to 4.2], third quartile, 4.4 cm [95% CI, 3.5 to 5.3], and fourth quartile, 3.6 cm [95% CI, 2.7 to 4.5]). Conclusion: This study shows that, after 1 year of CHT, breast development is modest and occurs primarily in the first 6 months. No clinical or laboratory parameters were found that predict breast development.
Authors: J V Gusmão-Silva; D C K Lichtenecker; L G A Ferreira; Í Gois; R Argeri; G N Gomes; M R Dias-da-Silva Journal: J Endocrinol Invest Date: 2022-06-11 Impact factor: 5.467
Authors: Jesús Manuel García-Acosta; Rosa María San Juan-Valdivia; Alfredo David Fernández-Martínez; Nieves Doria Lorenzo-Rocha; Maria Elisa Castro-Peraza Journal: Int J Environ Res Public Health Date: 2019-12-19 Impact factor: 3.390
Authors: Chantal M Wiepjes; Christel Jm de Blok; Annemieke S Staphorsius; Nienke M Nota; Mariska C Vlot; Renate T de Jongh; Martin den Heijer Journal: J Bone Miner Res Date: 2019-10-07 Impact factor: 6.741
Authors: Anne F Klassen; Manraj Kaur; Natasha Johnson; Baudewijntje Pc Kreukels; Giancarlo McEvenue; Shane D Morrison; Margriet G Mullender; Lotte Poulsen; Mujde Ozer; Will Rowe; Thomas Satterwhite; Kinusan Savard; John Semple; Jens Ahm Sørensen; Tim C van de Grift; Maeghan van der Meij-Ross; Danny Young-Afat; Andrea L Pusic Journal: BMJ Open Date: 2018-10-21 Impact factor: 2.692
Authors: Brendan J Nolan; Adam Brownhill; Ingrid Bretherton; Peggy Wong; Susan Fox; Peter Locke; Nicholas Russell; Mathis Grossmann; Jeffrey D Zajac; Ada S Cheung Journal: Ther Adv Endocrinol Metab Date: 2020-05-24 Impact factor: 3.565